The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in ...
Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...
AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain ...
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) Friday said the National Medical Products Administration (NMPA) in China has ...